PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|February 6, 2023
Fluid Air Launches Enhanced Magnaflo Filter Blowback System
Author(s)Pharmaceutical Technology Editors
Improvements to Fluid Air’s Magnaflo filter blowback system are intended to increase powder yield in PolarDry Models 001 and 004.
Advertisement
Fluid Air, a division of Spraying Systems, announced the launch of its enhanced Magnaflo assembly on Feb. 2, 2023. The upgrades are intended to increase powder yield through a more effective method of clearing product from the process filters.
The Magnaflo is a filter blowback system compatible with the PolarDry Models 001 and 004 electrostatic spray dryers, According to a company press release, the upgraded system is designed to speed up feed rates, ease processing of fine and sticky particles, and reduce both energy and nitrogen consumption.
“We are committed to continuous improvement,” said Michel Thenin, president, Fluid Air, in the release. “Our customers demand smart and efficient technology, and we are proud to add the enhanced Magnaflo system to our award-winning PolarDry product lineup.”
Source:
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
4
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
5